DRUG

Bright Minds Biosciences Inc.

Price Chart

Latest Quote

$75.92

+1.89 (+2.55%)

Current Price

Previous Close	$74.03
Open	$73.29
Day High	$77.17
Day Low	$71.05
Volume	296,600

Fetched: 2026-07-16T08:41:39

Stock Information

Note: Financial values converted from CAD to USD

Shares Outstanding	9.81M
Total Debt	$59K
Cash Equivalents	$220.89M
Net Income	$-19.51M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$746.89M
EPS (TTM)	$-2.46
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$437.28M
Income	$-19.51M
Book/sh	$22.38
Cash/sh	$31.56
Employees	26

Financial Ratios

Quick Ratio	81.10
Current Ratio	81.48
Debt/Eq	0.03

Returns & Margins

ROA	-10.44%
ROE	-15.02%

Ownership

Insider Ownership	12.00%
Institutional Ownership	92.92%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-8.84
P/B	3.40

Analyst Data

Recommendation	none
Target Price	$167.60

Technical Indicators

SMA20	$69.59
SMA50	$73.75
SMA200	$74.92
RSI	64.64
ATR	5.5664

Shares Float	5.13M
Short Float	12.60%
Short Ratio	2.13
Volatility	0.10
Rel Volume	0.53

Performance History

Week	-2.21%
Month	+27.25%
Quarter	-14.13%
6 Months	-15.63%
YTD	-8.79%
Year	+206.69%
3 Years	+2908.70%
5 Years	+224.12%
10 Years	+181.93%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-07-17	$76.12	157,400
2026-07-16	$74.23	329,600
2026-07-15	$75.92	297,400
2026-07-14	$74.03	249,100
2026-07-13	$75.93	389,900
2026-07-10	$77.84	331,400
2026-07-09	$78.20	218,800
2026-07-08	$69.88	254,100
2026-07-07	$64.64	254,200
2026-07-06	$66.65	320,800
2026-07-02	$67.60	234,700
2026-07-01	$66.54	576,300
2026-06-30	$70.20	259,500
2026-06-29	$69.18	335,400
2026-06-26	$65.79	365,200
2026-06-25	$63.64	152,400
2026-06-24	$66.22	347,900
2026-06-23	$65.13	235,200
2026-06-22	$63.49	348,100
2026-06-18	$60.66	239,400

About Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

📰 Latest News

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

Motley Fool • 2026-05-21T21:51:11Z

What Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate?

Insider Monkey • 2026-03-25T05:34:11Z

Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results

TipRanks • 2026-03-06T15:15:45Z

Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials

Insider Monkey • 2026-02-19T02:31:00Z

Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why

Zacks • 2025-11-26T13:55:03Z

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet

Zacks • 2025-11-25T14:55:03Z

Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable

Zacks • 2025-10-15T12:50:03Z

Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade

Zacks • 2025-09-18T13:55:01Z

Large Patient Population Is Key Driver For Bright Minds' Growth

Benzinga • 2025-09-08T17:54:11Z

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Market Exclusive • 2025-09-07T21:29:39Z

Period:

Income Statement (Annual)

Metric	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$9,926,347	$2,010,375	$5,260,604	$10,665,261
Other Income Expense	$134,441	$-6,632	$10,105	$7,230
Net Non Operating Interest Income Expense	$1,082,165	$21,461	$0	$0
Operating Expense	$9,926,347	$2,010,375	$5,260,604	$10,665,261
Other Operating Expenses	$204,861	$140,436	$132,933	$173,121
Selling And Marketing Expense	$306,003	$29,628	$85,049	$393,038
General And Administrative Expense	$1,521,095	$999,908	$1,481,662	$1,423,838
Other Non Operating Income Expenses	-	-	-	$-173,121
Total Other Finance Cost	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-8,709,742	$-1,995,546	$-5,250,499	$-10,658,031
Net Interest Income	$1,082,165	$21,461	$0	$0
Interest Income	$1,082,165	$21,461	$0	$0
Normalized Income	$-8,844,182	$-1,988,914	$-5,260,604	$-10,665,261
Net Income From Continuing And Discontinued Operation	$-8,709,742	$-1,995,546	$-5,250,499	$-10,658,031
Net Income Common Stockholders	$-8,709,742	$-1,995,546	$-5,250,499	$-10,658,031
Net Income	$-8,709,742	$-1,995,546	$-5,250,499	$-10,658,031
Net Income Including Noncontrolling Interests	$-8,709,742	$-1,995,546	$-5,250,499	$-10,658,031
Net Income Continuous Operations	$-8,709,742	$-1,995,546	$-5,250,499	$-10,658,031
Pretax Income	$-8,709,742	$-1,995,546	$-5,250,499	$-10,658,031
Interest Income Non Operating	$1,082,165	$21,461	$0	$0
Operating Income	$-9,926,347	$-2,010,375	$-5,260,604	$-10,665,261
Special Income Charges	-	$0	$0	$-1,424
Per Share
Diluted EPS	$-1.27	$-0.46	$-1.41	$-4.32
Basic EPS	$-1.27	$-0.46	$-1.41	$-4.32
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-10,006,043	$-1,951,498	$-5,219,111	$-10,668,191
Total Unusual Items	$134,441	$-6,632	$10,105	$7,230
Total Unusual Items Excluding Goodwill	$134,441	$-6,632	$10,105	$7,230
Reconciled Depreciation	$54,745	$52,245	$51,599	$4,300
EBITDA (Bullshit earnings)	$-9,871,602	$-1,958,130	$-5,209,005	$-10,660,961
EBIT	$-9,926,347	$-2,010,375	$-5,260,604	$-10,665,261
Diluted Average Shares	$4,898,548	$3,069,702	$2,649,224	$1,759,407
Basic Average Shares	$4,898,548	$3,069,702	$2,649,224	$1,759,407
Diluted NI Availto Com Stockholders	$-8,709,742	$-1,995,546	$-5,250,499	$-10,658,031
Gain On Sale Of Security	$134,441	$-6,632	$10,105	$8,654
Research And Development	$7,894,387	$840,403	$3,560,960	$8,675,264
Selling General And Administration	$1,827,099	$1,029,536	$1,566,711	$1,816,876
Other Gand A	$1,166,914	$648,229	$657,986	$1,353,018
Salaries And Wages	$354,181	$351,679	$823,676	$70,820
Impairment Of Capital Assets	-	$0	$0	$1,424

Fetched: 2026-07-15

Balance Sheet (Annual)

Metric	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Assets
Net Tangible Assets	$58,432,394	$3,942,983	$4,699,249	$7,508,377
Total Assets	$60,125,020	$4,347,698	$4,899,275	$8,608,350
Total Non Current Assets	$79,744	$83,796	$47,299	$98,898
Current Assets	$60,045,276	$4,263,902	$4,851,976	$8,509,452
Prepaid Assets	$703,590	$154,282	$19,722	$117,106
Receivables	$294,189	$35,770	$26,338	$110,946
Taxes Receivable	$149,504	$35,770	$26,338	$81,560
Accrued Interest Receivable	$144,686	$0	-	-
Cash Cash Equivalents And Short Term Investments	$59,047,497	$4,073,850	$4,805,916	$8,281,400
Cash And Cash Equivalents	$59,047,497	$4,073,850	$4,805,916	$8,281,400
Cash Equivalents	$61,427	$61,427	$61,427	$61,427
Cash Financial	$58,986,070	$4,012,422	$4,744,488	$8,219,972
Goodwill And Other Intangible Assets	-	-	-	$0
Other Receivables	-	-	-	$29,386
Debt
Total Debt	$89,578	$84,723	$52,382	$99,645
Long Term Debt And Capital Lease Obligation	$29,378	$28,186	$0	$51,266
Current Debt And Capital Lease Obligation	$60,201	$56,537	$52,382	$48,378
Liabilities
Total Liabilities Net Minority Interest	$1,692,626	$404,714	$200,026	$1,099,973
Total Non Current Liabilities Net Minority Interest	$29,378	$28,186	$0	$51,266
Current Liabilities	$1,663,248	$376,528	$200,026	$1,048,707
Payables And Accrued Expenses	$1,603,048	$319,991	$147,644	$1,000,328
Payables	$1,218,069	$290,256	$129,839	$887,675
Accounts Payable	$1,218,069	$290,256	$129,839	$887,675
Equity
Common Stock Equity	$58,432,394	$3,942,983	$4,699,249	$7,508,377
Total Equity Gross Minority Interest	$58,432,394	$3,942,983	$4,699,249	$7,508,377
Stockholders Equity	$58,432,394	$3,942,983	$4,699,249	$7,508,377
Gains Losses Not Affecting Retained Earnings	$3,826,937	$2,853,335	$2,420,837	$1,765,876
Retained Earnings	$-33,173,077	$-24,463,336	$-22,467,790	$-17,217,291
Other Equity Interest	-	$324,459	$592,432	-
Other
Ordinary Shares Number	$5,438,209	$3,222,055	$2,686,470	$2,505,855
Share Issued	$5,438,209	$3,222,055	$2,686,470	$2,505,855
Tangible Book Value	$58,432,394	$3,942,983	$4,699,249	$7,508,377
Invested Capital	$58,432,394	$3,942,983	$4,699,249	$7,508,377
Working Capital	$58,382,028	$3,887,373	$4,651,950	$7,460,745
Capital Lease Obligations	$89,578	$84,723	$52,382	$99,645
Total Capitalization	$58,432,394	$3,942,983	$4,699,249	$7,508,377
Capital Stock	$87,778,535	$25,228,525	$24,153,770	$22,959,792
Common Stock	$87,778,535	$25,228,525	$24,153,770	$22,959,792
Long Term Capital Lease Obligation	$29,378	$28,186	$0	$51,266
Current Capital Lease Obligation	$60,201	$56,537	$52,382	$48,378
Current Accrued Expenses	$384,979	$29,735	$17,805	$112,654
Net PPE	$79,744	$83,796	$47,299	$98,898
Gross PPE	$79,744	$83,796	$47,299	$98,898
Leases	$79,744	$83,796	$47,299	$98,898
Properties	$0	$0	$0	$0
Other Properties	-	-	-	$98,898

Fetched: 2026-07-15

Cash Flow Statement (Annual)

Metric	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Free Cash Flow
Free Cash Flow	$-6,190,171	$-1,317,702	$-5,002,682	$-9,676,744
Operating Activities
Operating Cash Flow	$-6,190,171	$-1,317,702	$-5,002,682	$-9,676,744
Cash Flow From Continuing Operating Activities	$-6,190,171	$-1,317,702	$-5,002,682	$-9,676,744
Operating Gains Losses	$-222,696	$-7,212	$32,297	$-184,334
Financing Activities
Issuance Of Capital Stock	$58,469,885	$640,980	$867,104	$2,873,644
Financing Cash Flow	$60,941,167	$577,289	$1,559,494	$3,700,727
Cash Flow From Continuing Financing Activities	$60,941,167	$577,289	$1,559,494	$3,700,727
Net Other Financing Charges	$-256,490	-	$-19,212	$-569,745
Net Common Stock Issuance	$58,469,885	$640,980	$867,104	$2,873,644
Common Stock Issuance	$58,469,885	$640,980	$867,104	$2,873,644
Other
Repayment Of Debt	$-71,327	$-63,906	$-61,329	$-5,101
End Cash Position	$59,047,497	$4,073,850	$4,805,916	$8,281,400
Beginning Cash Position	$4,073,850	$4,805,916	$8,281,400	$14,073,083
Effect Of Exchange Rate Changes	$222,652	$8,347	$-32,297	$184,334
Changes In Cash	$54,750,996	$-740,413	$-3,443,187	$-5,976,017
Proceeds From Stock Option Exercised	$2,799,099	$215	$772,932	$1,401,928
Net Issuance Payments Of Debt	$-71,327	$-63,906	$-61,329	$-5,101
Net Long Term Debt Issuance	$-71,327	$-63,906	$-61,329	$-5,101
Long Term Debt Payments	$-71,327	$-63,906	$-61,329	$-5,101
Change In Working Capital	$395,267	$28,355	$-670,692	$515,728
Change In Payables And Accrued Expense	$1,202,994	$172,347	$-852,684	$545,537
Change In Prepaid Assets	$-549,308	$-134,560	$97,384	$2,691
Change In Receivables	$-258,420	$-9,432	$84,608	$-32,500
Other Non Cash Items	$25,533	$6,371	$14,066	$20,955
Stock Based Compensation	$2,266,721	$598,085	$820,548	$623,215
Depreciation Amortization Depletion	$54,745	$52,245	$51,599	$4,300
Depreciation And Amortization	$54,745	$52,245	$51,599	$4,300
Depreciation	$54,745	$52,245	$51,599	$4,300
Net Foreign Currency Exchange Gain Loss	$-222,696	$-7,212	$32,297	$-184,334
Net Income From Continuing Operations	$-8,709,742	$-1,995,546	$-5,250,499	$-10,658,031
Asset Impairment Charge	-	$0	$0	$1,424
Change In Other Current Liabilities	-	-	-	$1,548

Fetched: 2026-07-15